HUSCAP logo Hokkaido Univ. logo

Hokkaido University Collection of Scholarly and Academic Papers >
北海道大学病院  >
雑誌発表論文等  >

Computed tomography (CT)-assessed bronchodilation induced by inhaled indacaterol and glycopyrronium/indacaterol in COPD


Online.docxSupplementary data34.26 kBMicrosoft Word XML見る/開く
RespirMed119_70.pdf528.69 kBPDF見る/開く

タイトル: Computed tomography (CT)-assessed bronchodilation induced by inhaled indacaterol and glycopyrronium/indacaterol in COPD
著者: Shimizu, Kaoruko 著作を一覧する
Seto, Ruriko 著作を一覧する
Makita, Hironi 著作を一覧する
Suzuki, Masaru 著作を一覧する
Konno, Satoshi 著作を一覧する
Ito, Yoichi M. 著作を一覧する
Kanda, Rie 著作を一覧する
Ogawa, Emiko 著作を一覧する
Nakano, Yasutaka 著作を一覧する
Nishimura, Masaharu 著作を一覧する
キーワード: Bronchodilation
β2 agonists
Pulmonary function tests
Three-dimensional computed tomography
発行日: 2016年10月
出版者: Elsevier
誌名: Respiratory medicine
巻: 119
開始ページ: 70
終了ページ: 77
出版社 DOI: 10.1016/j.rmed.2016.08.020
抄録: Background: Our previous studies suggested that the site of bronchodilation on CT might differ between inhaled β2 agonists and inhaled anticholinergics in COPD. Aim: To assess and compare the bronchodilation effects of inhaled indacaterol and glycopyrronium/indacaterol by airway generation in large airways using CT. Methods: CT scans at full inspiration and pulmonary function tests were done in 25 patients with moderate-severe COPD before and 4-5 weeks after daily inhalation of indacaterol and again another 4-5 weeks after inhalation of glycopyrronium/indacaterol. Airway inner luminal area (Ai) at the 3rd (segmental) to 6th generation of 8 selected bronchi, a total of 32 sites, in the right lung was analyzed on 3 occasions. Our proprietary software enables us to select the same airways and the same measurement sites for comparison, with simultaneous confirmation using two screens on the computer. Results: The overall increase of Ai (ΔAi, %) averaged at all 32 measurement sites induced by glycopyrronium/indacaterol had a significant correlation with FEV1 improvement (r=0.7466, p<0.0001). Both ΔAi, % with indacaterol and ΔAi, % with additional glycopyrronium were significant at the 3rd to 6th generations. Remarkable increases in ΔAi, % were found at the 5th and 6th generations in several subjects with indacaterol or additional glycopyrronium. There were no significant site-differences in the bronchodilation pattern caused by indacaterol and by glycopyrronium/indacaterol at any of the 3rd to 6th generations. Conclusions: Additional bronchodilation with glycopyrronium was demonstrated by CT at the 3rd to 6th generations, with no site-specific differences in bronchodilation between indacaterol and glycopyrronium/indacaterol. This study was registered in the UMIN Clinical Trials Registry (UMIN-CTR) system ( ID. UMIN000012043).
Rights: © 2016. This manuscript version is made available under the CC-BY-NC-ND 4.0 license
資料タイプ: article (author version)
出現コレクション:雑誌発表論文等 (Peer-reviewed Journal Articles, etc)

提供者: 清水 薫子


本サイトに関するご意見・お問い合わせは repo at へお願いします。 - 北海道大学